90
Participants
Start Date
June 13, 2022
Primary Completion Date
March 23, 2023
Study Completion Date
April 10, 2023
JNJ-77242113
JNJ-77242113 will be administered orally as delayed release tablets.
Placebo
Matching placebo will be administered orally as delayed release tablets.
Hosp. Univ. San Cecilio, Granada
Universitaetsmedizin Rostock, Rostock
The Pennsylvania Centre for Dermatology, LLC, Exton
Lawrence J Green MD LLC, Rockville
Universitatsklinikum Schleswig Holstein Campus Lubeck, Lübeck
CHRU Brest - Hopital Morvan, Brest
CHU de Grenoble Hopital Albert Michallon, La Tronche
Privatpraxis Dr. Hilton & Partner, Düsseldorf
Dermatology Specialists, Louisville
Hosp. Virgen Macarena, Seville
Universitatsklinikum Munster, Münster
Hosp. Univ. de Cruces, Barakaldo
Hautarztpraxis, Bramsche
Polyclinique de Courlancy, Reims
Health Concepts, Rapid City
Northshore University Healthsystem, Skokie
Universitatsklinikum Frankfurt, Frankfurt am Main
Epiphany Dermatology of Kansas, LLC, Overland Park
Unity Clinical Research, Oklahoma City
Arlington Center for Dermatology, Arlington
Stoll Dermatology, Beverly Hills
ActivMed Practices and Research, Beverly
ActivMed Practices and Research, Portsmouth
Windsor Dermatology, PC, East Windsor
Dermatology Research Institute Inc, Calgary
The Guenther Dermatology Research Centre, London
Lynderm Research Inc., Markham
DermEdge Research, Mississauga
Toronto Research Centre, Toronto
CHU de Nice Hopital de l Archet, Nice
Universitatsklinikum Carl Gustav Carus Dresden, Dresden
Specderm Poznanska sp j, Bialystok
Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna, Krakow
Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna, Lodz
Janssen Research & Development, LLC
INDUSTRY